Clik here to view.
Otsuka Pharmaceutical to Acquire Visterra
TOKYO & WALTHAM, Mass. Otsuka Pharmaceutical Co., Ltd. (Otsuka) and Visterra, Inc. (Visterra) announce that they have entered into a definitive merger agreement pursuant to which Otsuka will...
View ArticleClik here to view.
Phase 3 Trial of NINLARO® (ixazomib) as Maintenance Therapy Met Primary...
CAMBRIDGE, Mass. & OSAKA, Japan Takeda Pharmaceutical Company Limited (TSE: 4502) today announced that the randomized, Phase 3 TOURMALINE-MM3 study met its primary endpoint, demonstrating...
View ArticleClik here to view.
克林顿总统将在第7届世界患者安全科技峰会上发表有关杜绝院内可预防死亡的闭幕词
加州尔湾 (美国商业资讯) — 美国前总统比尔·克林顿将连续第7年在世界患者安全科技峰会上会晤医疗保健领袖和发表闭幕词，此次峰会将于2019年1月18日和19日在加州亨廷顿海滩召开。 本新闻稿包含多媒体。此处查看新闻稿全文： https://www.businesswire.com/news/home/20180711005915/zh-CN/...
View ArticleClik here to view.
クリントン元大統領が第7回年次世界患者安全・科学・技術サミットで病院での予防可能な死亡の根絶に関し閉会基調講演を実施へ
米カリフォルニア州アーバイン （ビジネスワイヤ） — 2019年1月18日、19日にカリフォルニア州のハンチントンビーチで開催する第7回年次世界患者安全・科学・技術サミットで、クリントン合衆国元大統領が7年連続で、医療分野のリーダーらを前に閉会基調講演を行います。 本プレスリリースではマルチメディアを使用しています。リリースの全文はこちらをご覧ください。：...
View ArticleClik here to view.
Arcus Biosciences Announces That Taiho Pharmaceutical Has Exercised Its...
HAYWARD, Calif. Arcus Biosciences, Inc. (NYSE:RCUS), a clinical-stage biopharmaceutical company focused on creating innovative cancer immunotherapies, today announced that Taiho Pharmaceutical Co.,...
View ArticleClik here to view.
EUSA Pharma：NICE核准靶向癌症免疫治疗药物QARZIBA®▼ (dinutuximab beta)用于治疗高危神经母细胞瘤患儿
英格兰赫默尔亨普斯特德 (美国商业资讯) — EUSA Pharma今天迎来了国立卫生和医护示范研究院(NICE)的一项决定，推荐靶向抗癌免疫治疗药物QARZIBA® (dinutuximab beta)用于治疗英格兰和威尔士NHS内的高危神经母细胞瘤患儿i。高危神经母细胞瘤是一种侵犯型神经母细胞瘤，后者是儿童期最常见的起源于脑外的实体瘤ii。dinutuximab...
View ArticleClik here to view.
維持療法としてのニンラーロ（イキサゾミブ）を検討する第3相試験は主要評価項目を達成し、移植後の多発性骨髄腫患者で無増悪生存期間の統計的に有意な改善を実証
米マサチューセッツ州ケンブリッジ & 大阪 （ビジネスワイヤ） — 武田薬品工業株式会社（TSE:...
View ArticleClik here to view.
NINLARO® (ixazomib)维持治疗3期试验达到主要终点，显示多发性骨髓瘤移植后患者的无进展生存延长有统计学意义
马萨诸塞州剑桥和日本大阪 (美国商业资讯) — 武田药品工业株式会社(TSE: 4502)今天宣布，3期TOURMALINE-MM3随机研究达到主要终点，显示NINLARO®...
View ArticleClik here to view.
EUSA Pharma：NICEが高リスク神経芽腫の小児患者の治療薬として分子標的がん免疫療法剤QARZIBA®▼（ジヌツキシマブベータ）を承認
英へメルヘムステッド （ビジネスワイヤ） — EUSA...
View ArticleClik here to view.
Phase III CAPSTONE-2 Study Showed That Baloxavir Marboxil Reduced Symptoms in...
SOUTH SAN FRANCISCO, Calif. Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), today announced that the Phase III CAPSTONE-2 study assessing the safety and efficacy of baloxavir...
View ArticleClik here to view.
Can-Fite Granted Australian and Chinese Patents for Erectile Dysfunction Drug
PETACH TIKVA, Israel Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE:CFBI), a biotechnology company advancing a pipeline of proprietary small molecule drugs that address liver diseases,...
View ArticleClik here to view.
FDA Clears First Nanotechnology Peek Devices for Spinal Intervertebral Fusion
NASHUA, N.H. Vallum Corporation, a medical device company, today announced that it has received clearance from the U.S. Food and Drug Administration (FDA) to market a polyetheretherketone (PEEK)...
View ArticleClik here to view.
Blade Therapeutics Announces Initiation of Phase 1 Study of Lead Calpain...
SOUTH SAN FRANCISCO, Calif. Blade Therapeutics, a biopharmaceutical company advancing novel anti-fibrotic therapies, today announced the initiation of a Phase 1 clinical trial for its lead compound,...
View ArticleClik here to view.
Cullgen Announces Expanded Scientific Advisory Board
DELAWARE Cullgen Inc, (“Cullgen” or the “Company), a drug discovery company focused on development of drug candidates using uSMITE™ (ubiquitin mediated small molecule induced target elimination),...
View ArticleClik here to view.
Samsung BioLogics Streamlines Quality Document Management Globally With Veeva...
PLEASANTON, Calif. Veeva Systems (NYSE:VEEV) today announced that Samsung BioLogics selected Veeva Vault QualityDocs to modernize quality document management. Vault QualityDocs enables Samsung...
View ArticleClik here to view.
Hyleukin-7 Selected as a Korea Drug Development Fund (KDDF) Project for...
ROCKVILLE, Md. Genexine, a clinical stage biotechnology company developing innovative biologics, and its spin-off company in the US, NeoImmuneTech, Inc. (NIT), today announced that Hyleukin-7, their...
View ArticleClik here to view.
Quantapore Inc. Closes Series 3 Financing Round to Fund Beta Launch of DNA...
MENLO PARK, Calif. Quantapore Inc. announced the completion of a $15.55 million sale of Series 3 Preferred Stock led by Northern Light Venture Capital (NLVC). Tsingyuan Ventures and Sangel Venture...
View ArticleClik here to view.
Emmaus Life Sciences Announces the New England Journal of Medicine has...
TORRANCE, Calif. VIEW E-MEDIA KIT – Emmaus Life Sciences, Inc. (Emmaus) announced today that the New England Journal of Medicine (NEJM) has published the results of its 48-week phase 3 clinical...
View ArticleClik here to view.
New Phase 3 Data Show Investigational Subcutaneous Formulation of Vedolizumab...
OSAKA, Japan Takeda Pharmaceutical Company Limited [TSE:4502] (“Takeda”) today announced top-line results from the VISIBLE 1 clinical trial evaluating the efficacy and safety of an investigational...
View ArticleClik here to view.
Arcadia Biosciences and Shriram Bioseed Reach Milestone in Developing...
DAVIS, Calif. & HYDERABAD, India Arcadia Biosciences, Inc. (Nasdaq: RKDA), an agricultural food ingredient company, and Shriram Bioseed, a leading research and hybrid seed development company,...
View Article